New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
18:43 EDTBMYBristol-Myers: AVERT trial shows high rates of DAS-defined remission
Bristol-Myers Squibb announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia, in combination with methotrexate achieved significantly higher rates of DAS-defined (DAS28 CRP <2.6) remission at 12 months than treatment with standard of care agent MTX - 60.9% vs. 45.2%, respectively, in biologic and MTX-naïve patients with early active RA. The data are being presented this week at the 2014 annual meeting of the European League Against Rheumatism. In this trial, known as AVERT, a co-primary endpoint assessed maintenance of remission following the withdrawal of all RA drug therapy including Orencia, MTX and steroids. A small but statistically significantly higher number of patients treated with Orencia plus MTX, versus MTX alone, for 12 months maintained remission 6 months after all RA treatment was withdrawn. Orencia was well tolerated in the study patients. In particular, serious adverse events, serious infection events and discontinuation due to serious adverse events were comparable to patients treated with MTX. “These data demonstrating higher remission rates and a similar safety profile for Orencia plus methotrexate versus methotrexate alone, in conjunction with insights from the withdrawal phase of the study, support the use of Orencia as a first line biologic therapy for patients with RA,” said Michael Giordano, senior vice president, head of development, Oncology and Immunology, Bristol-Myers Squibb.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information
September 5, 2014
16:45 EDTBMYMarket ends week little changed after mixed economic data
Subscribe for More Information
11:17 EDTBMYBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
September 4, 2014
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use